1H26 Appendix 4D and Financial Report

• Underlying net profit of $10.41M, at upper end of November 2025 guidance
• 1.8% decline in Group revenue driven by softer Australian IVF volumes
• Underlying EBITDA of $30.16M, down 15.3% on prior period

Monash IVF Group reported Underlying NPAT of $10.41M, at the upper end of the November 2025 profit guidance, representing a 34.0% decrease on the prior comparison period. Group revenue declined 1.8% to $137.86M, driven by a 2.9% decrease in Australian revenue due to softer domestic IVF market share and a 3% decline in ultrasound scan volumes, partly offset by growth in international revenue and genetics/ancillary income. Underlying EBITDA decreased 15.3% to $30.16M, with declines across the Australian IVF, international IVF, ultrasound and day surgery segments. Reported EBITDA decreased 30.2% due to one-off items. Depreciation and amortisation increased 10.6% reflecting higher IT system costs. Net finance costs rose $1.14M due to higher borrowing levels and non-cash interest expenses. The Australian segment reported a 29.5% decline in Underlying EBIT, while the international segment saw a 2.5% decrease.

Underlying NPAT of $10.41M for the half-year ended 31 December 2025.